Description: Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company's immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration.
Home Page: www.humanigen.com
HGEN Technical Analysis
830 Morris Turnpike
Short Hills,
NJ
07078-2625
United States
Phone:
973 200 3100
Officers
| Name | Title |
|---|---|
| Dr. Cameron Durrant M.D., MBA | Chairman, CEO, Principal Financial & Accounting Officer |
| Dr. Dale Chappell M.B.A., M.D., MBA | Chief Scientific Officer & Director |
| Mr. Robert Atwill M.B.A. | Sr. VP and Head of Asia-Pacific Region & Bus. Devel. |
| Mr. Edward P. Jordan M.B.A. | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 9.3897 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.2014 |
| Price-to-Sales TTM: | 4.4342 |
| IPO Date: | 2013-01-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |